

TEVA PHARMACEUTICAL INDUSTRIES LTD
Form SD
May 31, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM SD
SPECIALIZED DISCLOSURE REPORT

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Exact name of the registrant as specified in its charter)

ISRAEL 001-16174
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) Identification No.)

5 Basel Street, Petach Tikva, Israel 4951033
(Address of principal executive offices) (Zip code)
Eyal Desheh
Group Executive Vice President, Chief Financial Officer
Tel: 972-3-914-8171
(Name and telephone number, including area code, of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed and provide the period to which the information in this form applies:

Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2016.

Items 1.01 and 1.02 Conflict Minerals Disclosure, Exhibit
Conflict Minerals Disclosure and Report

A copy of the Company's Conflict Minerals Report is provided as Exhibit 1.02 hereto and is publicly available at

http://www.tevapharm.com/files/about/corporate_governance/governance_doc/Teva_Conflict_Minerals_Policy_Statement.pdf

Item 2.01 Exhibits

Listed below is the following exhibit filed as part of this report:

Exhibit 1.01 – Conflict Minerals Report as required by Item 1.01 and 1.02 of this Form.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Registrant)

/s/ Eyal Desheh_____

By Eyal Desheh
Group Executive Vice President, Chief Financial Officer
May 31, 2017